US regulators issued a flurry of letters calling out pharmaceutical companies for allegedly misleading ads, part of a promised Trump administration crackdown on the industry’s ubiquitous TV spots, and warned Eli Lilly & Co. and Novo Nordisk A/S about their blockbuster obesity drug marketing.

See Full Page